With its recent clinical trial stumble and falling revenues for its only approved drug on the market, Sage may be in trouble.
News & Analysis: Sage Therapeutics
The company, which failed pivotal clinical trials investigating major depression, aims to reverse its fortunes this year.
SAGE earnings call for the period ending March 31, 2020.
A revenue miss and a lack of news on its depression drug candidate had shareholders down in the dumps.
An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
Some bad news sent several stocks sharply lower.
An important clinical trial turned in underwhelming results.
A midsize acquisition seems imminent, and these two would fit like a glove.
Earning the first FDA approval for treating postpartum depression is a big step, but it's hardly an express ticket to profit town.
SAGE earnings call for the period ending December 31, 2018.